机译:佐剂Dabrafenib Plus Trametinib与Respbo患者切除,BRAF(V600) - 级,第III期(Combi-AD):从随机,第3阶段试验分析探索性生物标志物
Univ Hosp Zurich Skin Canc Ctr CH-8091 Zurich Switzerland;
Novartis Pharmaceut Basel Switzerland;
Novartis Inst BioMed Res Cambridge MA USA;
Novartis Inst BioMed Res Cambridge MA USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut Basel Switzerland;
Novartis Inst BioMed Res Cambridge MA USA;
Fdn IRCCS Ist Nazl Tumori Milan Italy;
Univ Queensland Princess Alexandra Hosp Gallipoli Med Res Fdn Brisbane Qld Australia;
Papa Giovanni XXIII Canc Ctr Hosp Bergamo Italy;
Veneto Inst Oncol IOV IRCCS Melanoma Oncol Unit Padua Italy;
Massachusetts Gen Hosp Ctr Canc Boston MA 02114 USA;
Royal Marsden NHS Fdn Trust London England;
Gustave Roussy &
Paris Sud Paris Saclay Univ Villejuif France;
Macquarie Univ Sydney NSW Australia;
Univ Pittsburgh UPMC Hillman Canc Ctr Melanoma Program Pittsburgh PA USA;
Univ Hosp Schleswig Holstein Kiel Germany;
Univ Hosp Essen Essen Germany;
Melanoma Inst Australia Sydney NSW Australia;
机译:佐剂Dabrafenib Plus Trametinib与Respbo患者切除,BRAF(V600) - 级,第III期(Combi-AD):从随机,第3阶段试验分析探索性生物标志物
机译:佐剂Dabrafenib加曲滴对切除BRAF(V600) - 矫正阶段III黑色素瘤的患者复发存活的有益效果似乎是短暂的
机译:dabrafenib和trametinib联合dabrafenib单药治疗BRAF V600转移性黑色素瘤患者的随机III期研究中与健康相关的生活质量影响
机译:更长的随访时间证实BRAF V600–Mutant III期恶性黑色素瘤切除术后辅佐达拉非尼+曲美替尼可无复发生存
机译:更长的随访证实复发的生存益处与佐剂Dabrafenib Plus Trametinib患者在切除的BRAF V600-突变阶段III黑色素瘤中